Adenosine: An old drug newly discovered

Anesthesiology

Volumn 111, Issue 4, 2009, Pages 904-915

  Eltzschig, Holger K ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE DIPHOSPHATE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; CD39 ANTIGEN; DIPYRIDAMOLE; HYPOXIA INDUCIBLE FACTOR 1;

ACUTE LUNG INJURY; BIOLOGICAL ACTIVITY; CELL METABOLISM; CLINICAL PRACTICE; DRUG MECHANISM; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; HYPEROXIA; HYPOXIA; IMMUNOCOMPETENT CELL; INFLAMMATION; INTESTINE EPITHELIUM; INTESTINE ISCHEMIA; KIDNEY ISCHEMIA; LIVER CELL; LIVER ISCHEMIA; MAMMAL; MUSCLE CELL; NONHUMAN; NUCLEOTIDE METABOLISM; PERIOPERATIVE PERIOD; PHYSICIAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCIENTIST; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

EID: 70349658872     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181b060f2     Document Type: Review

References (128)

1. Drury AN, Szent-Györgyi A: The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol 1929; 68:213-237
2. Belhassen B, Pelleg A: Electrophysiologic effects of adenosine triphosphate and adenosine on the mammalian heart: Clinical and experimental aspects. J Am Coll Cardiol 1984; 4:414-424
3. Delacrétaz E: Clinical practice. Supraventricular tachycardia. N Engl J Med 2006; 354:1039-1051
4. Blomstrm-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, Campbell WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CW Jr, Stevenson WG, Tomaselli GF, Antman EM, Smith SC Jr, Alpert JS, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Hiratzka LF, Hunt SA, Jacobs AK, Russell RO Jr, Priori SG, Blanc JJ, Budaj A, Burgos EF, Cowie M, Deckers JW, Garcia MA, Klein WW, Lekakis J, Lindahl B, Mazzotta G, Morais JC, Oto A, Smiseth O, Trappe HJ; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines. Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003; 108: 1871-1909
5. Stemp LI, Roy WL: Adenosine for the cardioversion of supraventricular tachycardia during general anesthesia and open heart surgery. ANESTHESIOLOGY 1992; 76:849-852
6. Trohman RG: Supraventricular tachycardia: Implications for the intensivist. Crit Care Med 2000; 28:N129-35
7. Robins K, Lyons G: Supraventricular tachycardia in pregnancy. Br J Anaesth 2004; 92:140-143
8. Plaschke K, Böckler D, Schumacher H, Martin E, Bardenheuer HJ: Ade-nosine-induced cardiac arrest and EEG changes in patients with thoracic aorta endovascular repair. Br J Anaesth 2006; 96:310-316
9. Fang TD, Lippmann M, Kakazu C, Donayre CE, Bui H, Kopchok GE, White RA: High-dose adenosine-induced asystole assisting accurate deployment of thoracic stent grafts in conscious patients. Ann Vasc Surg 2008; 22:602-607
10. Picano E, Trivieri MG: Pharmacologic stress echocardiography in the assessment of coronary artery disease. Curr Opin Cardiol 1999; 14:464-470
11. Hart ML, Köhler D, Eckle T, Kloor D, Stahl GL, Eltzschig HK: Direct treatment of mouse or human blood with soluble 5=-nucleotidase inhibits platelet aggregation. Arterioscler Thromb Vasc Biol 2008; 28:1477-1483
12. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359:1238-1251
13. Halker RB, Demaerschalk BM, Wellik KE, Wingerchuk DM, Rubin DI, Crum BA, Dodick DW: Caffeine for the prevention and treatment of postdural puncture headache: Debunking the myth. Neurologist 2007; 13:323-327
14. Hampl KF, Schneider MC, Rüttimann U, Ummenhofer W, Drewe J: Peri-operative administration of caffeine tablets for prevention of postoperative headaches. Can J Anaesth 1995; 42:789-792
15. Weber JG, Klindworth JT, Arnold JJ, Danielson DR, Ereth MH: Prophylactic intravenous administration of caffeine and recovery after ambulatory surgical procedures. Mayo Clin Proc 1997; 72:621-626
16. Fanta CH: Asthma. N Engl J Med 2009; 360:1002-1014
17. Fredholm BB: Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007; 14:1315-1323
18. Eltzschig HK, Thompson LF, Karhausen J, Cotta RJ, Ibla JC, Robson SC, Colgan SP: Endogenous adenosine produced during hypoxia attenuates neutro-phil accumulation: Coordination by extracellular nucleotide metabolism. Blood 2004; 104:3986-3992
19. Ohta A, Sitkovsky M: Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414:916-920
20. Sitkovsky M, Lukashev D: Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol 2005; 5:712-721
21. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M: Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004; 22:657-682
22. Thiel M, Chouker A, Ohta A, Jackson E, Caldwell C, Smith P, Lukashev D, Bittmann I, Sitkovsky MV: Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol 2005; 3:e174
23. Rosenberger P, Schwab JM, Mirakaj V, Masekowsky E, Mager A, Morote-Garcia JC, Unertl K, Eltzschig HK: Hypoxia-inducible factor-dependent induction of netrin-1 dampens inflammation caused by hypoxia. Nat Immunol 2009; 10: 195-202
24. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, Colgan SP: Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: Role of ectonucleotidases and adenosine A2B receptors. J Exp Med 2003; 198:783-796
25. Eltzschig HK, Weissmüller T, Mager A, Eckle T: Nucleotide metabolism and cell-cell interactions. Methods Mol Biol 2006; 341:73-87
26. Faigle M, Seessle J, Zug S, El Kasmi KC, Eltzschig HK: ATP release from vascular endothelia occurs across Cx43 hemichannels and is attenuated during hypoxia. PLoS One 2008; 3:e2801
27. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, Junger WG: ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 2006; 314:1792-1795
28. Eltzschig HK, Eckle T, Mager A, Küper N, Karcher C, Weissmüller T, Boengler K, Schulz R, Robson SC, Colgan SP: ATP release from activated neutro-phils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. Circ Res 2006; 99:1100-1108
29. Weissmüller T, Campbell EL, Rosenberger P, Scully M, Beck PL, Furuta GT, Colgan SP: PMNs facilitate translocation of platelets across human and mouse epithelium and together alter fluid homeostasis via epithelial cell-expressed ecto-NTPDases. J Clin Invest 2008; 118:3682-3692
30. Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K: Ectonucleoti-dases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost 2005; 31:217-233
31. Grenz A, Zhang H, Hermes M, Eckle T, Klingel K, Huang DY, Müller CE, Robson SC, Osswald H, Eltzschig HK: Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J 2007; 21:2863-2873
32. Köhler D, Eckle T, Faigle M, Grenz A, Mittelbronn M, Laucher S, Hart ML, Robson SC, Müller CE, Eltzschig HK: CD39/ectonucleoside triphosphate diphos-phohydrolase 1 provides myocardial protection during cardiac ischemia/reper-fusion injury. Circulation 2007; 116:1784-1794
33. Enjyoji K, Sévigny J, Lin Y, Frenette PS, Christie PD, Esch JS Imai M, Edelberg JM, Rayburn H, Lech M, Beeler DL, Csizmadia E, Wagner DD, Robson SC, Rosenberg RD: Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 1999; 5:1010-1017
34. Pinsky DJ, Broekman MJ, Peschon JJ, Stocking KL, Fujita T, Ramasamy R, Connolly ES Huang J, Kiss S, Zhang Y, Choudhri TF, McTaggart RA, Liao H, Drosopoulos JH, Price VL, Marcus AJ, Maliszewski CR: Elucidation of the throm-boregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest 2002; 109:1031-1040
35. Qawi I, Robson SC: New developments in anti-platelet therapies: Potential use of CD39/vascular ATP diphosphohydrolase in thrombotic disorders. Curr Drug Targets 2000; 1:285-296
36. Reutershan J, Vollmer I, Stark S, Wagner R, Ngamsri KC, Eltzschig HK: Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J 2009; 23:473-482
37. Friedman DJ, Rennke HG, Csizmadia E, Enjyoji K, Robson SC: The vascular ectonucleotidase ENTPD1 is a novel renoprotective factor in diabetic nephrop-athy. Diabetes 2007; 56:2371-2379
38. Dwyer KM, Robson SC, Nandurkar HH, Campbell DJ, Gock H, Murray-Segal LJ, Fisicaro N, Mysore TB, Kaczmarek E, Cowan PJ, d'Apice AJ: Thrombo-regulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 2004; 113:1440-1446
39. Eltzschig HK, Köhler D, Eckle T, Kong T, Robson SC, Colgan SP: Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 2009; 113: 224-232
40. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Pinsky DJ, Sesti C, Levi R: Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: Implications for ischemic vascular diseases. J Pharmacol Exp Ther 2003; 305:9-16
41. Eckle T, Füllbier L, Wehrmann M, Khoury J, Mittelbronn M, Ibla J, Rosen-berger P, Eltzschig HK: Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J Immunol 2007; 178:8127-8137
42. Beldi G, Wu Y, Sun X, Imai M, Enjyoji K, Csizmadia E, Candinas D, Erb L, Robson SC: Regulated catalysis of extracellular nucleotides by vascular CD39/ ENTPD1 is required for liver regeneration. Gastroenterology 2008; 135:1751-1760
43. Linden J: Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001; 41:775-787
44. Eckle T, Krahn T, Grenz A, Köhler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK: Cardioprotection by ecto-5=-nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007; 115:1581-1590
45. Grenz A, Zhang H, Eckle T, Mittelbronn M, Wehrmann M, Köhle C, Kloor D, Thompson LF, Osswald H, Eltzschig HK: Protective role of ecto-5=-nucleoti-dase (CD73) in renal ischemia. J Am Soc Nephrol 2007; 18:833-845
46. Hart ML, Henn M, Köhler D, Kloor D, Mittelbronn M, Gorzolla IC, Stahl GL, Eltzschig HK: Role of extracellular nucleotide phosphohydrolysis in intestinal ischemia-reperfusion injury. FASEB J 2008; 22:2784-2797
47. Hart ML, Much C, Gorzolla IC, Schittenhelm J, Kloor D, Stahl GL, Eltzschig HK: Extracellular adenosine production by ecto-5=-nucleotidase protects during murine hepatic ischemic preconditioning. Gastroenterology 2008; 135:1739-1750
48. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, Hansen KR, Thompson LF, Colgan SP: Ecto-5=-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 2002; 110:993-1002
49. Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC, Colgan SP: Crucial role for ecto-5=-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med 2004; 200:1395-1405
50. Louis NA, Robinson AM, MacManus CF, Karhausen J, Scully M, Colgan SP: Control of IFN-alphaA by CD73: Implications for mucosal inflammation. J Immunol 2008; 180:4246-4255
51. Hart ML, Jacobi B, Schittenhelm J, Henn M, Eltzschig HK: Cutting edge: A2B Adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury. J Immunol 2009; 182:3965-3968
52. Chen H, Yang D, Carroll SH, Eltzschig HK, Ravid K: Activation of the macrophage A2b adenosine receptor regulates tumor necrosis factor-alpha levels following vascular injury. Exp Hematol 2009; 37:533-538
53. Eckle T, Grenz A, Laucher S, Eltzschig HK: A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J Clin Invest 2008; 118:3301-3315
54. Eckle T, Köhler D, Lehmann R, El Kasmi K, Eltzschig HK: Hypoxia-inducible factor-1 is central to cardioprotection: A new paradigm for ischemic preconditioning. Circulation 2008; 118:166-175
55. Grenz A, Osswald H, Eckle T, Yang D, Zhang H, Tran ZV, Klingel K, Ravid K, Eltzschig HK: The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med 2008; 5:e137
56. Haskó G, Linden J, Cronstein B, Pacher P: Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008; 7:759-770
57. Fredholm BB, Irenius E, Kull B, Schulte G: Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 2001; 61:443-448
58. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK: A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 2008; 111: 2024-2035
59. Baraldi PG, Romagnoli R, Preti D, Fruttarolo F, Carrion MD, Tabrizi MA: Ligands for A2B adenosine receptor subtype. Curr Med Chem 2006; 13:3467-3482
60. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schönfeld C, Löffler M, Reyes G, Duszenko M, Karhausen J, Robinson A, Westerman KA, Coe IR, Colgan SP: HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med 2005; 202:1493-1505
61. Kong T, Westerman KA, Faigle M, Eltzschig HK, Colgan SP: HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J 2006; 20:2242-2250
62. van Calker D, Müller M, Hamprecht B: Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem 1979; 33:999-1005
63. Bruns RF, Lu GH, Pugsley TA: Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mol Pharmacol 1986; 29:331-346
64. Prystowsky EN, Niazi I, Curtis AB, Wilber DJ, Bahnson T, Ellenbogen K, Dhala A, Bloomfield DM, Gold M, Kadish A, Fogel RI, Gonzalez MD, Belardinelli L, Shreeniwas R, Wolff AA: Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), A novel A1-adenosine receptor agonist. J Am Coll Cardiol 2003; 42:1098-1102
65. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M: Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 1997; 388:674-678
66. Obata H, Li X, Eisenach JC: Spinal adenosine receptor activation reduces hypersensitivity after surgery by a different mechanism than after nerve injury. ANESTHESIOLOGY 2004; 100:1258-1262
67. Hansen PB, Schnermann J: Vasoconstrictor and vasodilator effects of adenosine in the kidney. Am J Physiol Renal Physiol 2003; 285:F590-9
68. Jin X, Shepherd RK, Duling BR, Linden J: Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J Clin Invest 1997; 100:2849-2857
69. Löffler M, Morote-Garcia JC, Eltzschig SA, Coe IR, Eltzschig HK: Physiological roles of vascular nucleoside transporters. Arterioscler Thromb Vasc Biol 2007; 27:1004-1013
70. Morote-Garcia JC, Rosenberger P, Kuhlicke J, Eltzschig HK: HIF-1-depen-dent repression of adenosine kinase attenuates hypoxia-induced vascular leak. Blood 2008; 111:5571-5580
71. Eltzschig HK, Faigle M, Knapp S, Karhausen J, Ibla J, Rosenberger P, Odegard KC, Laussen PC, Thompson LF, Colgan SP: Endothelial catabolism of extracellular adenosine during hypoxia: The role of surface adenosine deaminase and CD26. Blood 2006; 108:1602-1610
72. Van Linden A, Eltzschig HK: Role of pulmonary adenosine during hypoxia: Extracellular generation, signaling and metabolism by surface adenosine deami-nase/CD26. Expert Opin Biol Ther 2007; 7:1437-1447
73. Eckle T, Grenz A, Köhler D, Redel A, Falk M, Rolauffs B, Osswald H, Kehl F, Eltzschig HK: Systematic evaluation of a novel model for cardiac ischemic preconditioning in mice. Am J Physiol Heart Circ Physiol 2006; 291:H2533-40
74. Morote-Garcia JC, Rosenberger P, Nivillac NM, Coe IR, Eltzschig HK: Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. Gastroen-terology 2009; 136:607-618
75. Lloyd HG, Fredholm BB: Involvement of adenosine deaminase and aden-osine kinase in regulating extracellular adenosine concentration in rat hippocam-pal slices. Neurochem Int 1995; 26:387-395
76. Blackburn MR, Volmer JB, Thrasher JL, Zhong H, Crosby JR, Lee JJ, Kellems RE: Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J Exp Med 2000; 192:159-170
77. Blackburn MR: Too much of a good thing: Adenosine overload in adeno-sine-deaminase-deficient mice. Trends Pharmacol Sci 2003; 24:66-70
78. Decking UK, Schlieper G, Kroll K, Schrader J: Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ Res 1997; 81:154-164
79. Saito H, Nishimura M, Shinano H, Makita H, Tsujino I, Shibuya E, Sato F, Miyamoto K, Kawakami Y: Plasma concentration of adenosine during normoxia and moderate hypoxia in humans. Am J Respir Crit Care Med 1999; 159:1014-1018
80. Semenza GL: Life with oxygen. Science 2007; 318:62-64
81. Semenza GL: O2 sensing: Only skin deep? Cell 2008; 133:206-208
82. Semenza GL: HIF-1, O(2), and the 3 PHDs: How animal cells signal hypoxia to the nucleus. Cell 2001; 107:1-3
83. Sitkovsky MV: Damage control by hypoxia-inhibited AK. Blood 2008; 111:5424-5425
84. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seebal-luck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J, Taylor CT: Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hy-poxia-induced NFkappaB activity. Proc Natl Acad Sci U S A 2006; 103:18154-18159
85. Taylor CT: Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol 2008; 586:4055-4059
86. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, Karin M: NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008; 453:807-811
87. De Perrot M, Sekine Y, Fischer S, Waddell TK, McRae K, Liu M, Wigle DA, Keshavjee S: Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med 2002; 165:211-215
88. Naka Y, Toda K, Kayano K, Oz MC, Pinsky DJ: Failure to express the P-selectin gene or P-selectin blockade confers early pulmonary protection after lung ischemia or transplantation. Proc Natl Acad Sci U S A 1997; 94:757-761
89. Yang Z, Day YJ, Toufektsian MC, Ramos SI, Marshall M, Wang XQ, French BA, Linden J: Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 2005; 111:2190-2197
90. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH: Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 2004; 114:1098-1106
91. Robinson A, Keely S, Karhausen J, Gerich ME, Furuta GT, Colgan SP: Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 2008; 134:145-155
92. Peyssonnaux C, Datta V, Cramer T, Doedens A, Theodorakis EA, Gallo RL, Hurtado-Ziola N, Nizet V, Johnson RS: HIF-1alpha expression regulates the bactericidal capacity of phagocytes. J Clin Invest 2005; 115:1806-1815
93. Cummins EP, Seeballuck F, Keely SJ, Mangan NE, Callanan JJ, Fallon PG, Taylor CT: The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 2008; 134:156-165
94. Kempf VA, Lebiedziejewski M, Alitalo K, Wälzlein JH, Ehehalt U, Fiebig J, Huber S, Schütt B, Sander CA, Müller S, Grassl G, Yazdi AS, Brehm B, Autenrieth IB: Activation of hypoxia-inducible factor-1 in bacillary angiomatosis: Evidence for a role of hypoxia-inducible factor-1 in bacterial infections. Circulation 2005; 111:1054-1062
95. Ware LB, Matthay MA: The Acute Respiratory Distress Syndrome. N Engl J Med 2000; 342:1334-1349
96. Licker M, de Perrot M, Spiliopoulos A, Robert J, Diaper J, Chevalley C, Tschopp JM: Risk factors for acute lung injury after thoracic surgery for lung cancer. Anesth Analg 2003; 97:1558-1565
97. Milot J, Perron J, Lacasse Y, Létourneau L, Cartier PC, Maltais F: Incidence and predictors of ARDS after cardiac surgery. Chest 2001; 119:884-888
98. Shorr AF, Abbott KC, Agadoa LY: Acute respiratory distress syndrome after kidney transplantation: Epidemiology, risk factors, and outcomes. Crit Care Med 2003; 31:1325-1330
99. Volmer JB, Thompson LF, Blackburn MR: Ecto-5=-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury. J Immunol 2006; 176:4449-4458
100. Khoury J, Ibla JC, Neish AS, Colgan SP: Antiinflammatory adaptation to hypoxia through adenosine-mediated cullin-1 deneddylation. J Clin Invest 2007; 117:703-711
101. Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, Be-lardinelli L, Zeng D, Blackburn MR: Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 2006; 116:2173-2182
102. Reutershan J, Cagnina RE, Chang D, Linden J, Ley K: Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury. J Immunol 2007; 179:1254-1263
103. Hypoxia to the rescue: When oxygen therapies backfire. PLoS Biology 2005; 3:e211. Available at: http://www.plosbiology.org/article/info%3Adoi%2F10. 1371%2Fjournal.pbio.0030211
104. Weissmuller T, Eltzschig HK, Colgan SP: Dynamic purine signaling and metabolism during neutrophil-endothelial interactions. Purinergic Signal 2005; 1:229-239
105. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF; ACC/AHA TASK FORCE MEMBERS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW: ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116:1971-1996
106. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74:1124-1136
107. Downey JM, Davis AM, Cohen MV: Signaling pathways in ischemic preconditioning. Heart Fail Rev 2007; 12:181-188
108. Lankford AR, YangJN, Rose'Meyer R, French BA, Matherne GP, Fredholm BB, Yang Z: Effect of modulating cardiac A1 adenosine receptor expression on protection with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2006; 290:H1469-73
109. Armstrong S, Ganote CE: Adenosine receptor specificity in preconditioning of isolated rabbit cardiomyocytes: Evidence of A3 receptor involvement. Cardiovasc Res 1994; 28:1049-1056
110. Kin H, Zatta AJ, Lofye MT, Amerson BS, Halkos ME, Kerendi F, Zhao ZQ, Guyton RA, HeadrickJP, Vinten-JohansenJ: Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 2005; 67:124-133
111. Donato M, D'Annunzio V, Berg G, Gonzalez G, Schreier L, Morales C, Wikinski RL, Gelpi RJ: Ischemic postconditioning reduces infarct size by activation of A1 receptors and K+(ATP) channels in both normal and hypercholester-olemic rabbits. J Cardiovasc Pharmacol 2007; 49:287-292
112. Xi L, Das A, Zhao ZQ, Merino VF, Bader M, Kukreja RC: Loss of myocardial ischemic postconditioning in adenosine A1 and bradykinin B2 receptors gene knockout mice. Circulation 2008; 118:S32-7
113. Morrison RR, Tan XL, Ledent C, Mustafa SJ, Hofmann PA: Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postconditioning. Am J Physiol Heart Circ Physiol 2007; 293:H2523-9
114. Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV: Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc Res 2006; 70:308-314
115. Day YJ, Huang L, McDuffie MJ, Rosin DL, Ye H, ChenJF, Schwarzschild MA, Fink JS, Linden J, Okusa MD: Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 2003; 112:883-891
116. Day YJ, Huang L, Ye H, Li L, Linden J, Okusa MD: Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: The role of CD4+ T cells and IFN-gamma. J Immunol 2006; 176:3108-3114
117. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J: Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med 2006; 203:2639-2648
118. Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, Ravid K: The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 2006; 116:1913-1923
119. Yang D, Koupenova M, McCrann DJ, Kopeikina KJ, Kagan HM, Schreiber BM, Ravid K: The A2b adenosine receptor protects against vascular injury. Proc Natl Acad Sci USA 2008; 105:792-796
120. Frick JS, MacManus CF, Scully M, Glover LE, Eltzschig HK, Colgan SP: Contribution of adenosine A2B receptors to inflammatory parameters of experimental colitis. J Immunol 2009; 182:4957-4964
121. Hua X, Kovarova M, Chason KD, Nguyen M, Koller BH, Tilley SL: Enhanced mast cell activation in mice deficient in the A2b adenosine receptor. J Exp Med 2007; 204:117-128
122. Hasko G, Csoka B, Nemeth ZH, Vizi ES, Pacher P: A(2B) adenosine receptors in immunity and inflammation. Trends Immunol 2009; 30:263-270
123. Clark AN, Youkey R, Liu X, Jia L, Blatt R, Day YJ, Sullivan GW, Linden J, Tucker AL: A1 adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes. Circ Res 2007; 101:1130-1138
124. Zhang Y, Conklin DR, Li X, Eisenach JC: Intrathecal morphine reduces allodynia after peripheral nerve injury in rats via activation of a spinal A1 adenosine receptor. ANESTHESIOLOGY 2005; 102:416-420
125. Chiari AI, Eisenach JC: Intrathecal adenosine: Interactions with spinal clonidine and neostigmine in rat models of acute nociception and postoperative hypersensitivity. ANESTHESIOLOGY 1999; 90:1413-1421
126. Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B, Mahmarian JJ: Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging J Am Coll Cardiol 2005; 46:2069-2075
127. Leaker BR, O'Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, Lieu HD: Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 2008; 15:329-336
128. Laighold S, Druz R: Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis. J Nucl Cardiol 2009; 16:478-480